MedTrace Logo

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

NCT01276704 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-09-21

Study results available
· View outcomes & findings →

Summary

The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.

Conditions

Interventions

DRUG

Placebo

The placebo contains same filler materials as commercially available Brevail® but without active SDG.

DRUG

secoisolariciresinol

1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg

Sponsors & Collaborators

  • Lignan Research Inc.

    collaborator INDUSTRY

  • Carol Fabian, MD

    lead OTHER

Principal Investigators

  • Carol Fabian, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276704 on ClinicalTrials.gov